Marc Espié

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +15

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer

David Groheux, Sylvie Giacchetti, Jean‐Luc Moretti et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2010 · 399 citations

Medicine, Nuclear Medicine, Oncology +14

Phase I study of oxaliplatin in patients with advanced cancer

Jean Marc Extra, Marc Espié, Fabien Calvo et al. · Cancer Chemotherapy and Pharmacology · 1990 · 342 citations

Medicine, Oncology, Pharmacology +12

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

X. Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology · 2013 · 338 citations

Medicine, Oncology, Breast Oncology +14